TUESDAY, OCTOBER 24, 2017 |
| | Welcome, Introductions & Goals
by Program Chairs |
| | Session I
|
| | from Virology Education on Vimeo.  State of the ART: Integrase Inhibitors Resistance
Charles Boucher, MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands
|
| |  State of the ART: Integrase Inhibitors (clinical overview) (not yet available)
Jonathan Schapiro, MD
Sheba Medical Center, Ramat Gan, Israel
|
| | Session II
|
| | from Virology Education on Vimeo.  What is the virological support for reduced drug regimens?
Anne-Geneviève Marcelin, PharmD, PhD
Pitié Salpêtrière Hospital, Paris, France
|
| |  What is the clinical support for reduced drug regimens? (not available)
David Cooper, MD, DSc
University of New South Wales, Sydney, Australia |
| | 
Can we use HIV reservoir assays to predict VF in simplification strategies?
(not available)
Linos Vandekerckhove, MD, PhD
Ghent University Hospital, Ghent, Belgium |
| | Session III
|
| | from Virology Education on Vimeo.  Clinical case presentation
Christina Mussini, MD
University of Modena and Reggio Emilia, Modena, Italy
|
| | Oral abstract presentation |
| | No videos available for Abstract Presentations |
| | from Virology Education on Vimeo.  Clinical case presentation
Milosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
|
| | Session IV
|
| |  One pill a day?: Integration novel delivery systems into routine care
(not yet available)
Giovanni Di Perri, MD, PhD
University of Turin, Turin, Italy |
| | from Virology Education on Vimeo.  Prospects of immunotherapy for treatment
Michael Lederman, MD
Case Western Reserve University, Cleveland, Ohio, USA
|
What is the clinical support for reduced drug regimens? (not available)
One pill a day?: Integration novel delivery systems into routine care 
